Astellas Pharma Overview
- Founded
- 1923
- Status
- Public
- Employees
- 15,883
- Stock Symbol
- 4503
- Investments
- 26
- Share Price
- $16.29
- (As of Thursday Closing)
Astellas Pharma General Information
Description
Astellas Pharma Inc is a drug manufacturing company that sells pharmaceutical products across the globe. The vast majority of the company's revenue is derived from Japanese markets, followed by the Americas. Royalty income makes up a small percentage of Astellas' overall sales. Its largest therapeutic area by sales composition is oncology, followed by urology and transplantation. The company uses mergers and acquisitions as part of its long-term growth strategy. Astellas enters into strategic partnerships and licensing agreements to strengthen its commercialization platforms.
Contact Information
Website
Formerly Known As
Fujisawa Pharmaceutica, Yamanouchi Pharmaceutical
Ownership Status
Publicly Held
Financing Status
Corporate Backed or Acquired
Primary Industry
Pharmaceuticals
Other Industries
Biotechnology
Drug Discovery
Stock Exchange
TKS
Primary Office
- 2-5-1, Nihonbashi-Honcho
- Chuo-ku
- Tokyo, 103-8411
- Japan
+81 00-0000-0000
Astellas Pharma Stock Performance
(As of Thursday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $16.29 | $16.46 | $13.02 - $18.43 | $30.3B | 1.86B | 5.22M | $0.96 |
Astellas Pharma Financials Summary
|
In Thousands, USD |
TTM 30-Jun-2020 | FY 2020 31-Mar-2020 | FY 2019 31-Mar-2019 | FY 2018 31-Mar-2018 |
|---|---|---|---|---|
| EV | 32,426,090 | 27,636,821 | 25,970,880 | 27,115,502 |
| Revenue | 11,775,458 | 11,959,632 | 11,782,368 | 11,730,093 |
| EBITDA | 2,728,298 | 2,853,622 | 2,772,259 | 2,508,917 |
| Net Income | 1,731,689 | 1,796,561 | 2,004,679 | 1,485,562 |
| Total Assets | 20,966,687 | 21,449,934 | 17,114,508 | 17,485,709 |
| Total Debt | 4,125,764 | 4,394,981 | 604,422 | 536,191 |
Public Fundamental Data provided by Morningstar, Inc.
disclaimer
Astellas Pharma Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
This information is available in the PitchBook Platform. To explore Astellas Pharma‘s full profile, request access.
Request a free trialAstellas Pharma Comparisons
Description
Primary
Industry
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Astellas Pharma Inc is a drug manufacturing company that sells pharmaceutical products across the globe. The vast majori
Pharmaceuticals
Tokyo, Japan
15,883
As of 2020
000000000000
000000 0
illum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa
000000000000000
Tokyo, Japan
00000
As of 0000
00000000
0000 000
mpor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation
000000000000000
Petach Tikva, Israel
00000
As of 0000
00000
00000000000
00000
Add Comparison
PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.
Request a free trialAstellas Pharma Competitors (39)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Takeda Pharmaceutical Company | Corporation | Tokyo, Japan | 00000 | 00000000 | ||
| 0000 0000000000000 | Corporate Backed or Acquired | Petach Tikva, Israel | 00000 | 00000 | 00000000000 | 00000 |
| 000 000000 | Corporate Backed or Acquired | Monheim, Germany | 0000 | 000000&0 | ||
| 00000000 | Corporation | Basel, Switzerland | 000000 | 000000000000 | ||
| 000000000000000 | Corporation | Brentford, United Kingdom | 00000 | 00000000000 |
Astellas Pharma Executive Team (24)
Astellas Pharma Board Members (1)
| Name | Representing | Role | Since |
|---|---|---|---|
| 00000000 00000000 | Astellas Pharma | Chairman & Representative Director | 000 0000 |
Astellas Pharma Signals
Growth Rate
0.80%
Weekly
Growth
Growth
Weekly Growth
0.80%, 93rd %ile
-35.5%.
530%
Size Multiple
219x
Median
Size Multiple
219x, 100th %ile
0.00x
0.95x.
413Kx
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.
Request a free trialAstellas Pharma Investments & Acquisitions (26)
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| 00000 000000000000 | 21-Apr-2020 | 000000000000000000 | 000.00 | Biotechnology | 00000 00000000 00.0 |
| 00000000 000000000 | 15-Jan-2020 | 000000000000000000 | 00.000 | Biotechnology | 00000 00000000 00.0 |
| 000000 00000000000 | 26-Dec-2019 | 000000000000000000 | 00000 | Biotechnology | 00000 00000000 00.0 |
| 000000 0000000000 | 28-Oct-2019 | 00000 | 0000 | Enterprise Systems (Healthcare) | |
| LabCentral | 04-Oct-2019 | Corporate | 0000 | Other Commercial Services |
Astellas Pharma Subsidiaries (11)
| Company Name | Industry | Location | Founded |
|---|---|---|---|
| Xyphos Biosciences | Biotechnology | South San Francisco, CA | 2017 |
| 0000000 0000000000 | Biotechnology | Cambridge, MA | 0000 |
| 000000000 00000 | Biotechnology | Seattle, WA | 0000 |
| 00000 000000000000 | Biotechnology | Cambridge, United Kingdom | 0000 |
| 00000000 000000000 | Biotechnology | San Francisco, CA | 0000 |
Astellas Pharma Exits (6)
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| 000000 000 | 02-Jun-2015 | 00000 00000 00 | 000.00 | Completed |
|
| 000000 000 | 29-May-2015 | 00000 0000000 | 00000 | Completed |
|
| 00000 00000000 000 | 01-Oct-2013 | 00000 0000000 | Completed |
|
|
| 0000000 (000000000 | 22-Jun-2009 | 000000000 00000 00 | 0000 | Completed |
|
| FibroGen | 10-Jan-2007 | Later Stage VC | 0000 | Completed |
|